Drug Trial Radar · NCT01454063
Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Last checked: Nov 20, 2026Latest source record: Aug 21, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
405
Actual
Start
Sep 2011
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Omeros CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of OMS302 (the study drug) for maintaining intraoperative mydriasis in individuals undergoing Intraocular Lens Replacement (ILR) surgery.
Conditions
- Intraocular Lens Replacement
Interventions
OMS302Drug
OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
PlaceboDrug
Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During SurgeryTime frame: from surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure)
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Chandler, Arizona
Site not named
Glendale, Arizona
Site not named
Los Angeles, California
Site not named
Cape Coral, Florida
Site not named
Fort Myers, Florida
Site not named
Stuart, Florida
Site not named
Bloomington, Minnesota
Site not named
St Louis, Missouri
Site not named
Washington, Missouri
Site not named
Albuquerque, New Mexico
Site not named
New York, New York
Site not named
Goodlettsville, Tennessee
Site not named
Austin, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.